BENIGNI, ARIELA,ZOJA, CARLA,REMUZZI, GIUSEPPE MARIO NEGRI INSTITUTE,GIANNELLA-BORRADORI, ATHOS
申请号：
PL05775408
公开号：
PL1799230T3
申请日:
2005.08.25
申请国别(地区):
PL
年份:
2013
代理人:
摘要：
The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.
